Clinical Trial Aimed to Supplement Current Research Findings on the
Treatment of Localized Prostate Cancer
TORONTO, Nov. 14 /CNW/ -- A Canadian study on High Intensity Focused
Ultrasound therapy with the Sonablate(R) 500 - a Health Canada approved
treatment for localized prostate cancer - is underway at Can-Am HIFU. Through
funding from AstraZeneca Canada Inc, Can-Am HIFU, a prostate cancer treatment
centre, will conduct an REB/Health Canada approved clinical trial. The
objective of the study is to supplement current research findings on safety
and efficacy of HIFU therapy in the treatment of localized prostate cancer.
The trial will measure both the biochemical (PSA) cure rates and the
Biopsy-proven cure rates at one year.
"AstraZeneca is committed to promoting excellence in Canadian health
science research and to supporting the growth of Canada's scientific
community," says Marc Zarenda, Scientific Director - Oncology at AstraZeneca
Canada Inc. "We are excited to put our support behind this clinical trial."
The nation-wide study will involve a select number of men and will be led
by Can-Am HIFU urologists Jack Barkin, MD; Laurence Klotz, MD; Sender
Herschorn, MD; Neil Fleshner, MD; Michael Robinette, MD; Antonio Finelli, MD;
and Sidney Radomski, MD. The study will play an integral role in building
Canadian data on HIFU therapy.
Currently, the data on HIFU are from studies conducted in other
countries," said Dr. Barkin, Chief of Staff, Humber River Regional Hospital
and Director of Can-Am HIFU. "As more patients are considering HIFU as an
alternative treatment option for prostate cancer, we recognize the need to
build Canadian data on HIFU therapy."
HIFU has been used in several countries for a number of years to treat
men with localized prostate cancer and benign prostatic hyperplasia. The
therapy uses ultrasound energy to heat and destroy specifically targeted areas
of the prostate. HIFU was approved for use in the treatment of prostate cancer
in Canada in June 2005. Can-Am HIFU urologists have been treating patients
from Canada and abroad on an out-patient basis since March 2006. Currently the
Sonablate(R) 500 is undergoing clinical trials in the United States and has
not been approved for U.S. marketing by the FDA.
For more information on the study please contact Can-Am HIFU at 1 -877-
787-5906. For more information on HIFU with the Sonablate(R) 500, please visit
About Can-Am HIFU
Can-Am HIFU is a Canadian entity of USHIFU, LLC. The clinic, located in
Toronto, was established in March 2006 and solely treats localized prostate
cancer using HIFU with the Sonablate(R) 500. Can-Am HIFU physicians include
Jack Barkin, MD; Laurence Klotz, MD; Sender Herschorn, MD; Neil Fleshner, MD;
Michael Robinette, MD; Antonio Finelli, MD; and Sidney Radomski, MD.
USHIFU, LLC is a development company headquartered in Charlotte, NC.
USHIFU is the exclusive distributor of the Sonablate(R) 500 in North, South
and Central America, the island nations of the Caribbean and South Africa. The
company holds a minority ownership position in Focus Surgery Inc. of
Indianapolis, the world leader in the development of HIFU products and the
manufacturer of the Sonablate(R) 500 in conjunction with Misonix, Inc (MSON).
For further information:
For further information: Nora Ansah, Administrative Marketing Assistant
for USHIFU, LLC, +1-416-924-9760 Web Site: http://www.internationalhifu.com/